NCT06602219

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 222 (actual)
• Sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	LY4100511	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2024-10-25
• Primary completion: 2025-07-24
• Completion: 2025-09-04
• First posted: 2024-09-19
• Last updated: 2025-09-12

Locations

58 sites across 7 countries: United States, Canada, Czechia, Germany, Hungary, Japan, Poland

Regulatory

• FDA-regulated drug study